Urologic Cancers News
A high monocyte-to-lymphocyte ratio and a high platelet-to-lymphocyte ratio were predictive of poor OS in patients with advanced gallbladder cancer treated with chemotherapy.
Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.
About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.
New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus.
Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.
Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone.
As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.
Postoperative radiation therapy with adjuvant chemotherapy prolonged disease-free survival and overall survival in patients with locally advanced urothelial carcinoma.
In a study of patients receiving non-surgical treatment for localized upper tract urothelial carcinoma, radiation or chemotherapy provided no overall survival benefit.
Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.
Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.
New evidence suggests variation in the bacterial composition of urine is associated with response BCG among patients with non-muscle-invasive bladder cancer.
Obesity in childhood and adolescence may be related to the disproportionate rise in certain obesity-related cancers in younger adults, according to authors.
Researchers found no significant difference in 30-day postoperative complications between patients who received neoadjuvant chemotherapy and those who did not.
New study finds a prevalence of benign pathologic findings after PN of 30.9%.
Older patients should be routinely assessed prior to radical cystectomy to guide both
preoperative and postoperative care.
An established chemoradiation regimen is compared with gemcitabine and once-daily radiation in the selective bladder-sparing treatment of muscle-invasive bladder cancer.
Researchers theorize that KPNA2 expression could be used in the future to stratify risk groups among patients with renal cell carcinoma (RCC).
A review article examines the challenges in pathologic staging and grade reporting for patients with renal cell carcinoma.
Insights into controversial results of trials evaluating adjuvant vascular endothelial growth factor tyrosine kinase inhibitors in high-risk renal cell carcinoma.